Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taletrectinib in ROS1-positive advanced non-small cell lung cancer and other solid tumors
2024-516604-41-00Phase 2Authorised
- Sponsor
- Nuvation Bio
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of taletrectinib in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (6 cohorts), sponsored by Nuvation Bio. Primary endpoints: Confirmed objective response rate and Cohort 6 primary endpoint. Planned start Aug 2022; status: authorised.
02
Drugs
taletrectinib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-516604-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516604-41-00.